ArticleCrohn's & colitis 3602026
Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study.
Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02914535 (A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Filgotinib is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for ulcerative colitis. This interim analysis assessed long-term outcomes of filgotinib in Japanese patients with moderate-to-severe ulcerative colitis. Methods: In the long-term extension of the phase 2b/3 SELECTION trial (SELECTIONLTE; NCT02914535), SELECTION completers (Week 10 responders) continued filgotinib 200 mg (FIL200), filgotinib 100 mg (FIL100), or placebo, and non-responders received FIL200. Here, safety was evaluated over ⁓4 years in Japanese patients who received FIL200 in SELECTIONLTE using exposure-adjusted incidence rates (EAIRs) per 100 censored patient-years of exposure (cPYE). Efficacy was assessed over 96 weeks in Japanese completers and 144 weeks in Japanese non-responders who received filgotinib (FIL200 for completers; FIL100 or FIL200 for non-responders) in SELECTION and FIL200 in SELECTIONLTE by partial Mayo Clinic Score (pMCS), inflammatory biomarkers, and health-related quality of life (HRQoL). Results: This analysis included 86 patients (15 completers, 37 non-responders). EAIRs for all infections and herpes zoster were 54.4 and 3.9 per 100 cPYE, respectively. Among completers, the pMCS remission rate increased (LTE Week 96: 69%); and HRQoL and biomarker remission rates remained >50% (LTE Week 96: 85% and 54%, respectively). In non-responders, pMCS, HRQoL, and biomarker remission rates increased (LTE Week 144: 69%, 62%-67% and 60%-69%, respectively). Conclusions: Filgotinib demonstrated an acceptable long-term benefit-risk profile in Japanese patients, maintaining and improving symptomatic and HRQoL remission for up to 3 years. Japanese patients had a numerically higher incidence of infections and herpes zoster than the overall SELECTIONLTE population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.